Colossal Biosciences: 2025 TIME100 Most Influential CompaniesExtinction ain’t what it used to be. Around one-third of all existing species could vanish due to global warming by 2050 according to ...

11 analysts have expressed a variety of opinions on Avidity Biosciences RNA over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot ...

Truist lowered the firm’s price target on IGM Biosciences (IGMS) to $1 from $2 and keeps a Hold rating on the shares. The firm has updated tis model to reflect Q1 financial results and the ...

Get the latest Avidity Biosciences, Inc. (RNA) stock news and headlines to help you in your trading and investing decisions.

Forte Biosciences (FBRX) announces public offering of stock & pre-funded warrants. Funds to fuel R&D, clinical trials & operations.

By Denny Jacob Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

LifT Biosciences leases lab space at Texas Medical Center's Helix Park, expanding its innovative cancer immunotherapy research to the U.S.

Director Kevin Buehler of Precision Biosciences INC (NASDAQ: DTIL) recently purchased 5,076 shares of common stock, according to a Form 4 filing. The transactions, which occurred on June 25, 2025 ...

Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the ...

Investing.com - Wells Fargo initiated coverage on Ideaya Biosciences (NASDAQ: IDYA) with an overweight rating and a price target of $44.00 on Thursday. The research firm cited potential ...